BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Whittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev. 2007;33:146-160. [PMID: 17275192 DOI: 10.1016/j.ctrv.2006.08.006] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Sica A, Vitiello P, Sagnelli C, Sagnelli E, Argenziano G, Troiani T, Casale B, Mottola M. Extracorporeal photopheresis in elderly patient with refractory mycosis fungoides. Gazz Med Ital - Arch Sci Med 2022;181. [DOI: 10.23736/s0393-3660.20.04383-1] [Reference Citation Analysis]
2 Atci T, Baykal C. Efficacy of narrow-band ultraviolet-B therapy in patch-stage mycosis fungoides: A clinical study and review of the literature. Photodermatol Photoimmunol Photomed 2020;36:271-7. [PMID: 32145109 DOI: 10.1111/phpp.12547] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
3 Campbell BA, Ryan G, McCormack C, Tangas E, Bressel M, Twigger R, Buelens O, van der Weyden C, Prince HM. Lack of Durable Remission with Conventional-Dose Total Skin Electron Therapy for the Management of Sezary Syndrome and Multiply Relapsed Mycosis Fungoides. Cancers (Basel) 2019;11:E1758. [PMID: 31717353 DOI: 10.3390/cancers11111758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 Chellakhi M, Khalfaoui I, Benchakroun N, Bouchbika Z, Jouhadi H, Tawfiq N, Sahraoui S, Benider A, Chellakhi N, Quessar A. Radiation therapy in mycosis fungoid patient. Pan Afr Med J 2019;33:227. [PMID: 31692791 DOI: 10.11604/pamj.2019.33.227.17701] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Lopez AT, Bates S, Geskin L. Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma. Am J Clin Dermatol 2018;19:805-19. [PMID: 30173294 DOI: 10.1007/s40257-018-0380-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
6 Purnak S, Azar J, Mark LA. Etoposide as a single agent in the treatment of mycosis fungoides: A retrospective analysis. Dermatologic Therapy 2018;31. [DOI: 10.1111/dth.12586] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
7 Ghiciuc CM, Strat AL, Ochiuz L, Lupusoru CE, Ignat M, Vasile A, Grigorovici A, Stoleriu I, Solcan C. Inhibition of bcl-2 and cox-2 Protein Expression after Local Application of a New Carmustine-Loaded Clinoptilolite-Based Delivery System in a Chemically Induced Skin Cancer Model in Mice. Molecules 2017;22:E2014. [PMID: 29156646 DOI: 10.3390/molecules22112014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
8 Wilcox RA. Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 2017;92:1085-102. [PMID: 28872191 DOI: 10.1002/ajh.24876] [Cited by in Crossref: 80] [Cited by in F6Publishing: 84] [Article Influence: 13.3] [Reference Citation Analysis]
9 Puno MIBL, Dimagiba MTE, Jamora MJJ, Montinola FL, Tinio PT. Granulomatous slack skin presenting as diffuse poikiloderma and necrotic ulcers, with features of granulomatous vasculitis and response to oral prednisone, acitretin, and oral psoralen plus ultraviolet light therapy-A case report. JAAD Case Rep 2017;3:294-300. [PMID: 28748211 DOI: 10.1016/j.jdcr.2017.03.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Kelati A, Gallouj S, Tahiri L, Harmouche T, Mernissi FZ. Defining the mimics and clinico-histological diagnosis criteria for mycosis fungoides to minimize misdiagnosis. Int J Womens Dermatol 2017;3:100-6. [PMID: 28560304 DOI: 10.1016/j.ijwd.2016.11.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
11 Whittaker S, Hoppe R, Prince HM. How I treat mycosis fungoides and Sézary syndrome. Blood 2016;127:3142-53. [DOI: 10.1182/blood-2015-12-611830] [Cited by in Crossref: 77] [Cited by in F6Publishing: 82] [Article Influence: 11.0] [Reference Citation Analysis]
12 Patir P, Vural F. Treatment of mycosis fungoides, in the era of stem cell transplantation. World J Dermatol 2016; 5(1): 52-56 [DOI: 10.5314/wjd.v5.i1.52] [Reference Citation Analysis]
13 Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 2016;91:151-65. [PMID: 26607183 DOI: 10.1002/ajh.24233] [Cited by in Crossref: 81] [Cited by in F6Publishing: 88] [Article Influence: 11.6] [Reference Citation Analysis]
14 Hughes CF, Newland K, Mccormack C, Lade S, Prince HM. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers: Mycosis fungoides and Sézary syndrome. Australasian Journal of Dermatology 2016;57:182-91. [DOI: 10.1111/ajd.12349] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
15 Hu SCS. Mycosis fungoides and Sézary syndrome: Role of chemokines and chemokine receptors. World J Dermatol 2015; 4(2): 69-79 [DOI: 10.5314/wjd.v4.i2.69] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
16 Hughes CFM, Khot A, Mccormack C, Lade S, Westerman DA, Twigger R, Buelens O, Newland K, Tam C, Dickinson M, Ryan G, Ritchie D, Wood C, Prince HM. Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood 2015;125:71-81. [DOI: 10.1182/blood-2014-07-588236] [Cited by in Crossref: 137] [Cited by in F6Publishing: 139] [Article Influence: 17.1] [Reference Citation Analysis]
17 Slama S, Besbes R. Stereoselective synthesis of erythro-β-chloroamines and their conversion into functionalized trans-oxazolidin-2-ones. Tetrahedron 2014;70:4732-7. [DOI: 10.1016/j.tet.2014.05.063] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
18 Wilcox RA. Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014;89:837-51. [PMID: 25042790 DOI: 10.1002/ajh.23756] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
19 Iwatsuki K, Hamada T; Japanese Skin Cancer Society - Lymphoma Study Group. Current therapy of choice for cutaneous lymphomas: Complementary to the Japanese Dermatological Association/Japanese Skin Cancer Society guidelines. J Dermatol 2014;41:43-9. [DOI: 10.1111/1346-8138.12346] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
20 Baykal C, Yazganoğlu KD. Cutaneous Lymphomas. Clinical Atlas of Skin Tumors 2014. [DOI: 10.1007/978-3-642-40938-7_14] [Reference Citation Analysis]
21 Sung JJ, Karagiannis TC. Combination Therapy for Cancer: Phototherapy and HDAC Inhibition. Molecular mechanisms and physiology of disease 2014. [DOI: 10.1007/978-1-4939-0706-9_17] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Atalla A, Hallack Neto AE, Siqueira DB, Toledo GC. Allogeneic hematopoietic stem cell transplantation in mycosis fungoides. An Bras Dermatol 2013;88:216-9. [PMID: 24346924 DOI: 10.1590/abd1806-4841.20132365] [Reference Citation Analysis]
23 McGraw AL. Romidepsin for the treatment of T-cell lymphomas. Am J Health Syst Pharm 2013;70:1115-22. [PMID: 23784158 DOI: 10.2146/ajhp120163] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
24 Hensley FW, Major G, Edel C, Hauswald H, Bischof M. Technical and dosimetric aspects of the total skin electron beam technique implemented at Heidelberg University Hospital. Rep Pract Oncol Radiother 2014;19:135-43. [PMID: 24936332 DOI: 10.1016/j.rpor.2013.07.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
25 Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Syst Rev 2013;:CD008908. [PMID: 23986525 DOI: 10.1002/14651858.CD008908.pub3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
26 Mazzeo E, Rubino L, Buglione M, Antognoni P, Magrini SM, Bertoni F, Parmiggiani M, Barbieri P, Bertoni F. The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: Principles and indications. Rep Pract Oncol Radiother 2014;19:77-91. [PMID: 24936325 DOI: 10.1016/j.rpor.2013.07.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
27 Benton EC, Crichton S, Talpur R, Agar NS, Fields PA, Wedgeworth E, Mitchell TJ, Cox M, Ferreira S, Liu P. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer. 2013;49:2859-2868. [PMID: 23735705 DOI: 10.1016/j.ejca.2013.04.018] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 8.5] [Reference Citation Analysis]
28 Fernández-guarino M, Jaén-olasolo P. Terapia fotodinámica en micosis fungoides. Actas Dermo-Sifiliográficas 2013;104:393-9. [DOI: 10.1016/j.ad.2012.11.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
29 Fernández-Guarino M, Jaén-Olasolo P. Photodynamic therapy in mycosis fungoides. Actas Dermosifiliogr 2013;104:393-9. [PMID: 23664412 DOI: 10.1016/j.adengl.2012.11.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
30 Fernandez-Guarino M. Emerging treatment options for early mycosis fungoides. Clin Cosmet Investig Dermatol 2013;6:61-9. [PMID: 23450851 DOI: 10.2147/CCID.S27482] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
31 Beylot-barry M, Dereure O. Recommandations pour le traitement des lymphomes T cutanés. Les lymphomes cutanés 2013. [DOI: 10.1007/978-2-8178-0354-8_25] [Reference Citation Analysis]
32 Schlaak M, Theurich S, Pickenhain J, Skoetz N, Kurschat P, von Bergwelt-baildon M. Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: A systematic review. Critical Reviews in Oncology/Hematology 2013;85:21-31. [DOI: 10.1016/j.critrevonc.2012.06.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
33 Nasto LA, Wang D, Robinson AR, Clauson CL, Ngo K, Dong Q, Roughley P, Epperly M, Huq SM, Pola E, Sowa G, Robbins PD, Kang J, Niedernhofer LJ, Vo NV. Genotoxic stress accelerates age-associated degenerative changes in intervertebral discs. Mech Ageing Dev 2013;134:35-42. [PMID: 23262094 DOI: 10.1016/j.mad.2012.11.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
34 Tomita H, Ogawa F, Kuwatsuka S, Toriyama F, Yasumoto S, Kamihira S, Utani A. Attenuation of an adult T-cell leukemia skin lesion after treatment of a concomitant herpes simplex infection: a case study. Virol J 2012;9:224. [PMID: 23021252 DOI: 10.1186/1743-422X-9-224] [Reference Citation Analysis]
35 Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Syst Rev. 2012;1:CD008908. [PMID: 22258991 DOI: 10.1002/14651858.cd008908.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
36 Balaban J. The Use of Methotrexate in Dermatology / Upotreba metotreksata u dermatologiji. Serbian Journal of Dermatology and Venerology 2011;3:137-144. [DOI: 10.2478/v10249-011-0045-5] [Reference Citation Analysis]
37 Wilcox RA. Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86:928-48. [PMID: 21990092 DOI: 10.1002/ajh.22139] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
38 Schlaak M, Kurschat P, Shimabukuro-vornhagen A, Scheid C, Chemnitz J, Stadler R, von Bergwelt-baildon M, Theurich S. Donor lymphocyte infusions combined with systemic PUVA/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation. Transplant Immunology 2011;25:163-6. [DOI: 10.1016/j.trim.2011.06.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
39 Querfeld C, Kuzel TM, Kim YH, Porcu P, Duvic M, Musiek A, Rook AH, Mark LA, Pinter-brown L, Hamid O, Lin B, Bian Y, Boye M, Day JM, Rosen ST. Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leukemia & Lymphoma 2011;52:1474-80. [DOI: 10.3109/10428194.2011.572265] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
40 Jurkovicova J, Xicoy B, Bielsa I, Arellano A. [Sustained molecular remission in an adult patient with Sézary syndrome after peripheral allogeneic stem-cell transplantation]. Med Clin (Barc) 2011;136:317-8. [PMID: 20462612 DOI: 10.1016/j.medcli.2010.03.009] [Reference Citation Analysis]
41 Zwischenberger BA, Pandya AG, Guitart J. Cutaneous T-cell Lymphoma. Cancer of the Skin 2011. [DOI: 10.1016/b978-1-4377-1788-4.00021-6] [Reference Citation Analysis]
42 Poligone B, Lin J, Chung C. Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma. Core Evid 2011;6:1-12. [PMID: 21468238 DOI: 10.2147/CE.S9084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
43 Schlaak M, Theurich S, Skoetz N, Pickenhain J, Engert A, Kurschat P, Bergwelt-baildon M. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T cell lymphoma. Cochrane Database of Systematic Reviews 2010. [DOI: 10.1002/14651858.cd008908] [Reference Citation Analysis]
44 Chandesris MO, Malamut G, Verkarre V, Meresse B, Macintyre E, Delarue R, Rubio MT, Suarez F, Deau-Fischer B, Cerf-Bensussan N, Brousse N, Cellier C, Hermine O. Enteropathy-associated T-cell lymphoma: a review on clinical presentation, diagnosis, therapeutic strategies and perspectives. Gastroenterol Clin Biol. 2010;34:590-605. [PMID: 21050687 DOI: 10.1016/j.gcb.2010.09.008] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
45 Fernández-guarino M, Harto A, Pérez-garcía B, Montull C, De Las Heras E, Jaén P. Micosis fungoide en fase de placas tratada con terapia fotodinámica: resultados en 12 pacientes. Actas Dermo-Sifiliográficas 2010;101:785-91. [DOI: 10.1016/j.ad.2010.06.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
46 Whittaker SJ, Demierre M, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, Mcculloch W, Kim YH. Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma. JCO 2010;28:4485-91. [DOI: 10.1200/jco.2010.28.9066] [Cited by in Crossref: 481] [Cited by in F6Publishing: 500] [Article Influence: 37.0] [Reference Citation Analysis]
47 Beylot-barry M, Dereure O, Vergier B, Barete S, Laroche L, Machet L, Delfau-larue M, D’incan M, Grange F, Ortonne N, Merlio J, Bagot M. Prise en charge des lymphomes T cutanés : recommandations du Groupe français d’étude des lymphomes cutanés. Annales de Dermatologie et de Vénéréologie 2010;137:611-21. [DOI: 10.1016/j.annder.2010.06.021] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
48 Choi J, Foss F. Cutaneous T-cell lymphoma: Biologic targets for therapy. Curr Hematol Malig Rep 2007;2:272-7. [PMID: 20425380 DOI: 10.1007/s11899-007-0037-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 D'hooghe M, Catak S, Stanković S, Waroquier M, Kim Y, Ha H, Van Speybroeck V, De Kimpe N. Systematic Study of Halide-Induced Ring Opening of 2-Substituted Aziridinium Salts and Theoretical Rationalization of the Reaction Pathways. Eur J Org Chem 2010;2010:4920-31. [DOI: 10.1002/ejoc.201000486] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 4.7] [Reference Citation Analysis]
50 Chandesris M, Malamut G, Verkarre V, Meresse B, Macintyre E, Delarue R, Rubio M, Suarez F, Deau-fischer B, Cerf-bensussan N, Brousse N, Cellier C, Hermine O. RETRAIT: Lymphomes T intestinaux associés à une entéropathie (maladie cœliaque et sprue réfractaire): présentation, diagnostic, prise en charge thérapeutique, pronostic et perspectives. Gastroentérologie Clinique et Biologique 2010. [DOI: 10.1016/j.gcb.2010.01.021] [Reference Citation Analysis]
51 Whittaker SJ. Cutaneous Lymphomas and Lymphocytic Infiltrates. Rook's Textbook of Dermatology 2010. [DOI: 10.1002/9781444317633.ch57] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
52 Hymes KB. The Role of Histone Deacetylase Inhibitors in the Treatment of Patients With Cutaneous T-Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia 2010;10:98-109. [DOI: 10.3816/clml.2010.n.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
53 Calzado-villarreal L, Polo-rodríguez I, Ortiz-romero P. Primary Cutaneous CD30+ Lymphoproliferative Disorders. Actas Dermo-Sifiliográficas (English Edition) 2010;101:119-128. [DOI: 10.1016/s1578-2190(10)70598-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
54 Calzado-villarreal L, Polo-rodríguez I, Ortiz-romero P. Síndrome linfoproliferativo CD30+ cutáneo primario. Actas Dermo-Sifiliográficas 2010;101:119-28. [DOI: 10.1016/j.ad.2009.07.019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
55 Fernández-guarino M, Harto A, Pérez-garcía B, Montull C, De Las Heras E, Jaén P. Plaque-Phase Mycosis Fungoides Treated with Photodynamic Therapy: Results from 12 Patients. Actas Dermo-Sifiliográficas (English Edition) 2010;101:785-91. [DOI: 10.1016/s1578-2190(10)70717-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
56 Kirby JS, Kim EJ, Rook AH. Therapy of Sézary syndrome. Expert Review of Dermatology 2009;4:567-579. [DOI: 10.1586/edm.09.57] [Reference Citation Analysis]
57 Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, Abuav R, Ricker JL, Rizvi S, Chen C, Boileau K, Gunchenko A, Sanz-rodriguez C, Geskin LJ. Evaluation of the Long-Term Tolerability and Clinical Benefit of Vorinostat in Patients With Advanced Cutaneous T-Cell Lymphoma. Clinical Lymphoma and Myeloma 2009;9:412-6. [DOI: 10.3816/clm.2009.n.082] [Cited by in Crossref: 71] [Cited by in F6Publishing: 73] [Article Influence: 5.1] [Reference Citation Analysis]
58 Junkins-Hopkins JM. Immunomodulatory therapy of cutaneous T-cell lymphoma: a multimodality approach in advanced disease. J Am Acad Dermatol 2009;61:1056-8. [PMID: 19925930 DOI: 10.1016/j.jaad.2009.09.024] [Reference Citation Analysis]
59 Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sézary syndrome. Blood 2009;114:4337-53. [DOI: 10.1182/blood-2009-07-202895] [Cited by in Crossref: 108] [Cited by in F6Publishing: 115] [Article Influence: 7.7] [Reference Citation Analysis]
60 Nassem S, Kashyap R, Awasthi NP, Krishnani N, Kumari N. Sézary syndrome presenting with ‘leonine facies’. Australasian Journal of Dermatology 2009;50:285-8. [DOI: 10.1111/j.1440-0960.2009.00560.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
61 Doukaki S, Aricò M, Bongiorno MR. A Rare Presentation of Mycosis Fungoides Mimicking Psoriasis Vulgaris. Case Rep Dermatol 2009;1:60-5. [PMID: 20652117 DOI: 10.1159/000249148] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
62 Gardner JM, Introcaso CE, Nasta SD, Kim EJ, Vittorio CC, Rook AH. A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome. Journal of the American Academy of Dermatology 2009;61:112-6. [DOI: 10.1016/j.jaad.2008.11.889] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
63 Dereure O. Place de l’électronthérapie dans la prise en charge du mycosis fongoïde : des indications à optimiser et un accès à faciliter. Annales de Dermatologie et de Vénéréologie 2009;136:235-7. [DOI: 10.1016/j.annder.2008.10.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
64 Stadler R. Aktuelles zu kutanen Lymphomen. Fortschritte der praktischen Dermatologie und Venerologie 2009. [DOI: 10.1007/978-3-540-77148-7_13] [Reference Citation Analysis]
65 Ferenczi K, Baron ED. Light Therapies for Cutaneous T-Cell Lymphoma. Light-Based Therapies for Skin of Color 2009. [DOI: 10.1007/978-1-84882-328-0_8] [Reference Citation Analysis]
66 Sebastian Mestel D, Beyer M, Möbs M, Steinhoff M, Sterry W, Assaf C. Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome. Expert Opinion on Biological Therapy 2008;8:1929-39. [DOI: 10.1517/14712590802528696] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
67 Lansigan F, Choi J, Foss FM. Cutaneous T-cell Lymphoma. Hematology/Oncology Clinics of North America 2008;22:979-96. [DOI: 10.1016/j.hoc.2008.07.014] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
68 Mestel DS, Assaf C, Steinhoff M, Beyer M, Moebs M, Sterry W. Emerging drugs in cutaneous T cell lymphoma. Expert Opin Emerg Drugs 2008;13:345-61. [PMID: 18537525 DOI: 10.1517/14728214.13.2.345] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
69 Longo Imedio I. Dianas terapéuticas en los linfomas cutáneos. Piel 2008;23:321-327. [DOI: 10.1016/s0213-9251(08)71043-8] [Reference Citation Analysis]
70 D'hooghe M, De Kimpe N. Synthesis and synthetic applications of 2-amino-3-halo-1-oxypropanes. Tetrahedron 2008;64:3275-85. [DOI: 10.1016/j.tet.2008.01.048] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
71 D'hooghe M, Dekeukeleire S, De Kimpe N. Reactivity of N-(omega-haloalkyl)-beta-lactams with regard to lithium aluminium hydride: novel synthesis of 1-(1-aryl-3-hydroxypropyl)aziridines and 3-aryl-3-(N-propylamino)propan-1-ols. Org Biomol Chem 2008;6:1190-6. [PMID: 18362957 DOI: 10.1039/b719686e] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
72 Woo JH, Liu J, Kang SH, Singh R, Park SK, Su Y, Ortiz J, Neville DM, Willingham MC, Frankel AE. GMP production and characterization of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1) for phase I/II clinical trials. Protein Expression and Purification 2008;58:1-11. [DOI: 10.1016/j.pep.2007.11.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
73 Woo JH, Bour SH, Dang T, Lee YJ, Park SK, Andreas E, Kang SH, Liu JS, Neville DM Jr, Frankel AE. Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1). Cancer Immunol Immunother 2008;57:1225-39. [PMID: 18256829 DOI: 10.1007/s00262-008-0457-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
74 Duarte RF, Schmitz N, Servitje O, Sureda A. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant. 2008;41:597-604. [PMID: 18176611 DOI: 10.1038/sj.bmt.1705968] [Cited by in Crossref: 90] [Cited by in F6Publishing: 93] [Article Influence: 6.0] [Reference Citation Analysis]
75 Avilés A, Nambo MJ, Neri N, Castañeda C, Cleto S, Gonzalez M, Huerta-guzmán J. Interferon and Low Dose Methotrexate Improve Outcome in Refractory Mycosis Fungoides/Sézary Syndrome. Cancer Biotherapy and Radiopharmaceuticals 2007;22:836-40. [DOI: 10.1089/cbr.2007.0402] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
76 Longo DL. Watch out, MF! Blood 2007;110:1708-1709. [DOI: 10.1182/blood-2007-06-094896] [Reference Citation Analysis]